Biotecnofe Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
2
Biotecnofe General Information
Description
Developer of biotechnology products intended to serve the veterinary industry in sustainably and qualitatively feeding the planet. The company specializes in the research, development, and production of biotherapeutics, helping clients improve animal health and productivity.
Contact Information
Website
www.biotecnofe.com.arCorporate Office
- Route 168 Pje.el Pozo Ptlc
- Santa Fe, 3000
- Argentina
Corporate Office
- Route 168 Pje.el Pozo Ptlc
- Santa Fe, 3000
- Argentina
Biotecnofe Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biotecnofe Patents
Biotecnofe Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020418449-A1 | Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses | Active | 30-Dec-2019 | ||
| AU-2020418449-B2 | Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses | Active | 30-Dec-2019 | ||
| EP-4085071-A1 | Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses | Pending | 30-Dec-2019 | ||
| US-20230242608-A1 | Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses | Pending | 30-Dec-2019 | ||
| WO-2021136736-A1 | Method for obtaining a mammalian cell line that expresses a recombinant equine chorionic gonadotropin (recg), the recombinant cell lines producing recg, large-scale recg production method, recg, formulations containing recg, nucleic acids encoding for recg and uses | Inactive | 30-Dec-2019 | C12N15/86 |
Biotecnofe Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biotecnofe FAQs
-
When was Biotecnofe founded?
Biotecnofe was founded in 2018.
-
Where is Biotecnofe headquartered?
Biotecnofe is headquartered in Santa Fe, Argentina.
-
What industry is Biotecnofe in?
Biotecnofe’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Biotecnofe a private or public company?
Biotecnofe is a Private company.
-
What is Biotecnofe’s current revenue?
The current revenue for Biotecnofe is .
-
Who are Biotecnofe’s investors?
Parque Tecnologico Litoral Centro has invested in Biotecnofe.
-
When was Biotecnofe acquired?
Biotecnofe was acquired on 05-Dec-2022.
-
Who acquired Biotecnofe?
Biotecnofe was acquired by Ceva Santé Animale.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process